BioVie (NASDAQ:BIVI) Stock Rating Upgraded by Wall Street Zen

BioVie (NASDAQ:BIVI) was upgraded by Wall Street Zen to a “sell” rating in a research note issued on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioVie in a research note on Monday, April 20th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

BioVie Price Performance

Shares of NASDAQ BIVI opened at $1.80 on Friday. BioVie has a twelve month low of $1.06 and a twelve month high of $9.09. The stock has a market cap of $13.57 million, a price-to-earnings ratio of -0.73 and a beta of 0.57. The company’s fifty day moving average is $1.70 and its 200-day moving average is $1.47.

BioVie (NASDAQ:BIVI) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.03.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BIVI. DRW Securities LLC bought a new stake in shares of BioVie during the fourth quarter worth $149,000. Prosperity Wealth Management Inc. acquired a new stake in shares of BioVie during the third quarter worth $273,000. Prelude Capital Management LLC acquired a new stake in shares of BioVie during the third quarter worth $275,000. Citadel Advisors LLC bought a new stake in BioVie in the 3rd quarter valued at $199,000. Finally, Squarepoint Ops LLC bought a new stake in BioVie in the 3rd quarter valued at $63,000. Institutional investors own 4.59% of the company’s stock.

About BioVie

BioVie Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.

The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease.